Related references
Note: Only part of the references are listed.Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
Zena Wilson et al.
CANCER RESEARCH (2022)
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
A. N. J. Tutt et al.
ANNALS OF ONCOLOGY (2022)
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
L. Tobalina et al.
ANNALS OF ONCOLOGY (2021)
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2021)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
PARP Inhibitors - Trapped in a Toxic Love Affair
Dragomir B. Krastev et al.
CANCER RESEARCH (2021)
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Chunling Hu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
Leila Dorling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018
Rajesh Sharma
BREAST CANCER RESEARCH AND TREATMENT (2021)
Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
Marc Tischkowitz et al.
GENETICS IN MEDICINE (2021)
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2021)
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Ingrid A. Mayer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress
Rebecca L. Lloyd et al.
NUCLEIC ACIDS RESEARCH (2021)
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
Diana Zatreanu et al.
NATURE COMMUNICATIONS (2021)
Breast Cancer, Version 4.2021 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon et al.
NATURE REVIEWS CANCER (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)
Nadine Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers
Timothy A. Yap et al.
CANCER DISCOVERY (2020)
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Stephen J. Pettitt et al.
CANCER DISCOVERY (2020)
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Karen Pinilla Alba et al.
CANCER RESEARCH (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Johan Staaf et al.
NATURE MEDICINE (2019)
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors
Andrew Lee et al.
GENETICS IN MEDICINE (2019)
The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells
Gamze Guney Eskiler
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola et al.
CANCER CELL (2018)
The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer
Tuo Li et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
NCCN Guidelines Updates: Breast Cancer
Sharon H. Giordano et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Harveer Dev et al.
NATURE CELL BIOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
The shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Clinical implications of germline mutations in breast cancer: TP53
Katherine Schon et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study
H. S. Han et al.
ANNALS OF ONCOLOGY (2018)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Eileen E. Parkes et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
Elizabeth L. Christie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
J. K. Litton et al.
NPJ BREAST CANCER (2017)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Melissa C. Southey et al.
JOURNAL OF MEDICAL GENETICS (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
H. S. Rugo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu et al.
LANCET ONCOLOGY (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
Nigel Bundred et al.
INVESTIGATIONAL NEW DRUGS (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer
Rebecca A. Dent et al.
BREAST CANCER RESEARCH (2013)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Nasim Mavaddat et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts et al.
CANCER DISCOVERY (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Balancing repair and tolerance of DNA damage caused by alkylating agents
Dragony Fu et al.
NATURE REVIEWS CANCER (2012)
Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
Katharina Schlacher et al.
CELL (2011)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
Mary Ellen Moynahan et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
Deann P. Atchley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PARP inhibitor development for systemic cancer targeting
Tomasz Zaremba et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743
Daniele Grazziotin Soares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II
Alejandro D. Treszezamsky et al.
CANCER RESEARCH (2007)
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
Gad Rennert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
C. T. M. Brekelmans et al.
EUROPEAN JOURNAL OF CANCER (2007)
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
Nazneen Rahman et al.
NATURE GENETICS (2007)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
SR Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Interaction of the fanconi anemia proteins and BRCA1 in a common pathway
I Garcia-Higuera et al.
MOLECULAR CELL (2001)
Share Paper
